Revvity Inc (RVTY) Stock Price, Quote & News

Company Profile

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 781 663 6900

Website: www.revvity.com

Address:

77 4th Avenue, Waltham, United States

YouOnlyLiveTwice Apr. 29 at 3:06 PM

$RVTY This is how horribly managed this company is ..on May 13 they’re sending their VP of ESG to the BOA health care conference… To talk about what ? ESG? You can’t make this stuff up meanwhile the stock is at a 5 year low .. this entire management team needs to be fired . POS company

0 · Reply

YouOnlyLiveTwice Apr. 28 at 5:09 PM

$RVTY This is the performance of the current CEO and absolute disaster while making millions per year … Truly amazing how these BOD are useless ..this CEO should have been fired by now ..

0 · Reply

YouOnlyLiveTwice Apr. 23 at 5:11 PM

$RVTY @ a 5 year low Great job by this management team When you have a moment look at their salaries… Imagine the poor people who are non executive 401ks in 5 years 0 gain

0 · Reply

YouOnlyLiveTwice Apr. 23 at 2:50 PM

$RVTY What a F POS lol CEO making $4M per year this is what shareholders get …

1 · Reply

YouOnlyLiveTwice Apr. 17 at 6:54 PM

$RVTY Noticed there were millions $$ in puts …lmao Their getting roasted like a marshmallow

0 · Reply

YouOnlyLiveTwice Apr. 16 at 7:42 PM

$RVTY They fore this CEO yet? $4M a+ per year Complete disaster

0 · Reply

anachartanalyst Apr. 14 at 3:01 PM

$RVTY https://anachart.com/wp-content/uploads/ana_temp/1776178891_soc-img.jpg

0 · Reply

YouOnlyLiveTwice Apr. 2 at 4:05 PM

$RVTY Stock is under heavy accumulation

0 · Reply

YouOnlyLiveTwice Mar. 30 at 5:45 PM

$RVTY Stock is @ a 5 year low while the CEO is pulling in close to $4M salary Amazing how he still has a job .. Imagine working for this company

0 · Reply

YouOnlyLiveTwice Mar. 11 at 8:16 PM

$RVTY Why TF would anyone even commit a$1 to this company They go to 3 conferences no mention of any new partnerships , no update on guidance just whining about how the misconception of Cluade meanwhile this incompetent CEO who should go back to being a scientist is making $3.7M per year The top 5 people in this company make collectively over $10M per year and look at the results down well over 25% for the year

0 · Reply

Revvity Transcript: AGM 2026

Apr 16, 2026, 8:00 AM EDT - 13 days ago

Revvity to Present at Upcoming Investor Conferences

Apr 10, 2026, 8:00 AM EDT - 19 days ago

Revvity to Hold Earnings Call on Tuesday, May 5, 2026

Apr 9, 2026, 8:00 AM EDT - 20 days ago

Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows

Mar 10, 2026, 11:30 AM EDT - 7 weeks ago

Revvity Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 3, 2026, 2:30 PM EST - 2 months ago

Revvity Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:30 AM EST - 2 months ago

Revvity Transcript: 47th Annual Raymond James Institutional Investor Conference

Feb 5, 2026, 8:00 AM EST - 2 months ago

Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

Feb 3, 2026, 9:20 AM EST - 3 months ago

Revvity Analysts Boost Their Forecasts Following Better-Than-Expected Q4 Results

Feb 2, 2026, 10:28 AM EST - 3 months ago

Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers

Feb 2, 2026, 8:00 AM EST - 3 months ago

Revvity Earnings Call Transcript: Q4 2025

Feb 2, 2026, 7:13 AM EST - 3 months ago

Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

Feb 2, 2026, 6:00 AM EST - 3 months ago

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

Jan 26, 2026, 4:05 PM EST - 3 months ago

Revvity Board Declares Quarterly Dividend

Jan 13, 2026, 12:45 PM EST - 3 months ago

Revvity Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:51 AM EST - 3 months ago

Revvity Stock Jumps on Profit Outlook Hike. Why the Shares Are at a Crossroads.

Jan 12, 2026, 5:10 PM EST - 3 months ago

Revvity says it will exceed 2025 profit forecast range

Jan 12, 2026, 4:15 PM EST - 3 months ago

Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

Jan 9, 2026, 8:00 AM EST - 3 months ago

Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models

Dec 18, 2025, 8:00 AM EST - 4 months ago

Revvity to Present at J.P. Morgan Healthcare Conference

Dec 16, 2025, 8:00 AM EST - 4 months ago

Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery

Dec 2, 2025, 9:00 AM EST - 5 months ago

Revvity Transcript: Citi Annual Global Healthcare Conference 2025

Nov 18, 2025, 9:00 AM EST - 5 months ago

Revvity Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 8:00 AM EST - 6 months ago

Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy

Nov 10, 2025, 8:00 AM EST - 6 months ago

Revvity Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 7:45 AM EST - 6 months ago

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

Oct 28, 2025, 9:32 AM EDT - 6 months ago

Revvity Analysts Increase Their Forecasts After Q3 Earnings

Oct 27, 2025, 8:00 AM EDT - 6 months ago

Revvity Earnings Call Transcript: Q3 2025

Oct 27, 2025, 7:06 AM EDT - 6 months ago

Revvity lifts annual profit forecast on renewed demand in diagnostics unit

Oct 27, 2025, 6:00 AM EDT - 6 months ago

Revvity Announces Financial Results for the Third Quarter of 2025

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Revvity Showcases Progress with Purpose in 2025 Impact Report

Oct 6, 2025, 8:00 AM EDT - 7 months ago

Revvity to Hold Earnings Call on Monday, October 27, 2025

Oct 2, 2025, 8:00 AM EDT - 7 months ago

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

SNY

Sep 29, 2025, 8:00 AM EDT - 7 months ago

Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

Sep 22, 2025, 8:00 AM EDT - 7 months ago

Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems

Sep 9, 2025, 2:35 PM EDT - 8 months ago

Revvity Transcript: Baird Global Healthcare Conference 2025

Sep 3, 2025, 8:00 AM EDT - 8 months ago

Revvity Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 8:00 AM EDT - 8 months ago

Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

Aug 6, 2025, 8:00 AM EDT - 9 months ago

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

Jul 28, 2025, 1:40 PM EDT - 9 months ago

Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook

Jul 28, 2025, 12:25 PM EDT - 9 months ago

Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More

LNG NKE

Jul 28, 2025, 8:13 AM EDT - 9 months ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ATAI

Jul 28, 2025, 8:09 AM EDT - 9 months ago

Revvity trims 2025 profit forecast on soft demand for diagnostics in China

Jul 28, 2025, 8:00 AM EDT - 9 months ago

Revvity Earnings Call Transcript: Q2 2025

Jul 28, 2025, 7:39 AM EDT - 9 months ago

Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.

Jul 28, 2025, 6:00 AM EDT - 9 months ago

Revvity Announces Financial Results for the Second Quarter of 2025

Jul 7, 2025, 8:00 AM EDT - 10 months ago

Revvity to Hold Earnings Call on Monday, July 28, 2025

Jun 10, 2025, 8:00 AM EDT - 11 months ago

Revvity Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 2, 2025, 8:00 AM EDT - 11 months ago

Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows

May 19, 2025, 8:00 AM EDT - 1 year ago

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

May 13, 2025, 12:20 PM EDT - 1 year ago

Revvity Transcript: Bank of America 2025 Healthcare Conference

Apr 28, 2025, 9:14 AM EDT - 1 year ago

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Revvity Earnings Call Transcript: Q1 2025

Apr 28, 2025, 7:32 AM EDT - 1 year ago

Revvity beats quarterly estimates on steady demand for medical equipment

Apr 28, 2025, 6:00 AM EDT - 1 year ago

Revvity Announces Financial Results for the First Quarter of 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Revvity Fuels the Future of Cancer Science with New Research Solutions

RSSS

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Revvity to Hold Earnings Call on Monday, April 28, 2025

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

Mar 20, 2025, 1:00 PM EDT - 1 year ago

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

Mar 19, 2025, 9:00 AM EDT - 1 year ago

Revvity Transcript: KeyBanc Annual Health Care Forum 2025

Mar 11, 2025, 12:00 PM EDT - 1 year ago

PerkinElmer Acquires Project Farma, Expanding Its OneSource Professional Services Offering for the Life Sciences Industry

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Revvity Transcript: Leerink Global Healthcare Conference 2025

Mar 4, 2025, 9:10 AM EST - 1 year ago

Revvity Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay

Mar 3, 2025, 7:30 AM EST - 1 year ago

Revvity Transcript: Raymond James & Associates’ 46th Annual Institutional Investors Conference 2025

Feb 20, 2025, 12:30 PM EST - 1 year ago

Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group

Jan 31, 2025, 8:00 AM EST - 1 year ago

Revvity Earnings Call Transcript: Q4 2024

Jan 31, 2025, 7:32 AM EST - 1 year ago

Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending

Jan 31, 2025, 6:00 AM EST - 1 year ago

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024

Jan 13, 2025, 11:15 AM EST - 1 year ago

Revvity Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 3, 2024, 8:20 AM EST - 1 year ago

Revvity Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 21, 2024, 12:00 PM EST - 1 year ago

Revvity Transcript: Investor Day 2024

Nov 4, 2024, 8:00 AM EST - 1 year ago

Revvity Earnings Call Transcript: Q3 2024

Sep 10, 2024, 12:15 PM EDT - 1 year ago

Revvity Transcript: The Baird 2024 Global Healthcare Conference

Sep 4, 2024, 8:45 AM EDT - 1 year ago

Revvity Transcript: 2024 Wells Fargo Healthcare Conference

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Revvity Earnings Call Transcript: Q2 2024

Jun 10, 2024, 8:00 AM EDT - 2 years ago

Revvity Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 14, 2024, 11:40 AM EDT - 2 years ago

Revvity Transcript: BofA Securities Health Care Conference 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Revvity Earnings Call Transcript: Q1 2024

Mar 20, 2024, 9:00 AM EDT - 2 years ago

Revvity Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 12, 2024, 9:30 AM EDT - 2 years ago

Revvity Transcript: Barclays 26th Annual Global Healthcare Conference

Mar 5, 2024, 9:15 AM EST - 2 years ago

Revvity Transcript: 45th Annual Raymond James Institutional Investors Conference 2024

Mar 4, 2024, 9:10 AM EST - 2 years ago

Revvity Transcript: TD Cowen 44th Annual Health Care Conference

Feb 29, 2024, 8:00 AM EST - 2 years ago

Revvity Transcript: Citi’s 2024 Unplugged Medtech and Life Sciences Access Day

Feb 1, 2024, 8:00 AM EST - 2 years ago

Revvity Earnings Call Transcript: Q4 2023

Jan 9, 2024, 1:30 PM EST - 2 years ago

Revvity Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Nov 28, 2023, 9:10 AM EST - 2 years ago

Revvity Transcript: The 6th Annual Evercore ISI HealthCONx Conference

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Revvity Earnings Call Transcript: Q3 2023

Sep 14, 2023, 7:20 AM EDT - 2 years ago

Revvity Transcript: Bank of America Global Healthcare Conference

Sep 12, 2023, 9:40 AM EDT - 2 years ago

Revvity Transcript: Baird Global Healthcare Conference 2023

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Revvity Transcript: Wells Fargo Securities Healthcare Conference 2023

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Revvity Earnings Call Transcript: Q2 2023

Jun 13, 2023, 11:40 AM EDT - 3 years ago

Revvity Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

May 11, 2023, 8:00 AM EDT - 3 years ago

Revvity Earnings Call Transcript: Q1 2023

Mar 21, 2023, 2:15 PM EDT - 3 years ago

Revvity Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 14, 2023, 8:00 AM EDT - 3 years ago

Revvity Transcript: Barclays Global Healthcare Conference

Mar 6, 2023, 9:10 AM EST - 3 years ago

Revvity Transcript: Cowen Health Care Conference

Feb 14, 2023, 8:00 AM EST - 3 years ago

Revvity Earnings Call Transcript: Q4 2022

Jan 10, 2023, 11:30 AM EST - 3 years ago

Revvity Transcript: JPMorgan Healthcare Conference

Nov 8, 2022, 8:00 AM EST - 3 years ago

Revvity Earnings Call Transcript: Q3 2022

Aug 1, 2022, 9:30 AM EDT - 4 years ago

Revvity Earnings Call Transcript: Q2 2022

May 3, 2022, 6:52 AM EDT - 4 years ago

Revvity Earnings Call Transcript: Q1 2022

Feb 1, 2022, 2:43 PM EST - 4 years ago

Revvity Earnings Call Transcript: Q4 2021

Nov 1, 2021, 8:00 PM EDT - 4 years ago

Revvity Earnings Call Transcript: Q3 2021

Jul 26, 2021, 2:26 AM EDT - 5 years ago

Revvity Earnings Call Transcript: Q2 2021

Jun 24, 2021, 8:30 AM EDT - 5 years ago

Revvity Transcript: Investor Day 2021

May 3, 2021, 6:08 PM EDT - 5 years ago

Revvity Earnings Call Transcript: Q1 2021

Feb 2, 2021, 3:00 AM EST - 5 years ago

Revvity Earnings Call Transcript: Q4 2020

Oct 28, 2020, 4:00 AM EDT - 5 years ago

Revvity Earnings Call Transcript: Q3 2020

Jul 28, 2020, 3:00 AM EDT - 6 years ago

Revvity Earnings Call Transcript: Q2 2020

May 5, 2020, 5:00 PM EDT - 6 years ago

Revvity Earnings Call Transcript: Q1 2020

Jan 27, 2020, 5:00 PM EST - 6 years ago

Revvity Earnings Call Transcript: Q4 2019

Oct 30, 2019, 5:00 PM EDT - 7 years ago

Revvity Earnings Call Transcript: Q3 2019

Jul 29, 2019, 5:00 PM EDT - 7 years ago

Revvity Earnings Call Transcript: Q2 2019

Apr 25, 2019, 5:00 PM EDT - 7 years ago

Revvity Earnings Call Transcript: Q1 2019

Jan 31, 2019, 5:00 PM EST - 7 years ago

Revvity Earnings Call Transcript: Q4 2018

Oct 31, 2018, 5:00 PM EDT - 8 years ago

Revvity Earnings Call Transcript: Q3 2018

Aug 1, 2018, 5:00 PM EDT - 8 years ago

Revvity Earnings Call Transcript: Q2 2018

Apr 30, 2018, 5:00 PM EDT - 8 years ago

Revvity Earnings Call Transcript: Q1 2018

YouOnlyLiveTwice Apr. 29 at 3:06 PM

0 · Reply

YouOnlyLiveTwice Apr. 28 at 5:09 PM

$RVTY This is the performance of the current CEO and absolute disaster while making millions per year … Truly amazing how these BOD are useless ..this CEO should have been fired by now ..

0 · Reply

YouOnlyLiveTwice Apr. 23 at 5:11 PM

$RVTY @ a 5 year low Great job by this management team When you have a moment look at their salaries… Imagine the poor people who are non executive 401ks in 5 years 0 gain

0 · Reply

YouOnlyLiveTwice Apr. 23 at 2:50 PM

$RVTY What a F POS lol CEO making $4M per year this is what shareholders get …

1 · Reply

YouOnlyLiveTwice Apr. 17 at 6:54 PM

$RVTY Noticed there were millions $$ in puts …lmao Their getting roasted like a marshmallow

0 · Reply

YouOnlyLiveTwice Apr. 16 at 7:42 PM

$RVTY They fore this CEO yet? $4M a+ per year Complete disaster

0 · Reply

anachartanalyst Apr. 14 at 3:01 PM

$RVTY https://anachart.com/wp-content/uploads/ana_temp/1776178891_soc-img.jpg

0 · Reply

YouOnlyLiveTwice Apr. 2 at 4:05 PM

$RVTY Stock is under heavy accumulation

0 · Reply

YouOnlyLiveTwice Mar. 30 at 5:45 PM

$RVTY Stock is @ a 5 year low while the CEO is pulling in close to $4M salary Amazing how he still has a job .. Imagine working for this company

0 · Reply

YouOnlyLiveTwice Mar. 11 at 8:16 PM

0 · Reply

YouOnlyLiveTwice Mar. 10 at 6:49 PM

$RVTY The CEO and CFO have spoken 4x in the last 6 weeks and the stock has crashed 28 points ….thats all you need to know about this company CPOS

0 · Reply

YouOnlyLiveTwice Mar. 10 at 2:07 PM

$RVTY The CEO of this company makes over $3M per year in just salary Look at the stock performance over the last 3 years a complete disaster He should be fired as well as the BOD for paying him this amount of $$ ..

0 · Reply

YouOnlyLiveTwice Mar. 10 at 1:39 PM

$RVTY Another useless conference today. They go and say the same thing they said weeks ago during the ER call Every time he speaks expect the stock to go down If you don’t have anything “NEW” then don’t go and waste peoples time

0 · Reply

YouOnlyLiveTwice Mar. 6 at 7:07 PM

$RVTY At the conference on Wednesday that idiot CEO said there maximizing shareholder value … Really based on this 5 year chart? Really bid amazing how blind the BOD is

0 · Reply

YouOnlyLiveTwice Mar. 6 at 3:06 PM

$RVTY Sell the company and take your shareholders out of misery… CEO and CFO need to be fired

0 · Reply

YouOnlyLiveTwice Mar. 5 at 6:18 PM

$RVTY I don’t know why this idiotic CEO went to the conference on Wednesday…he basically said the same thing he said on the ER call then whine about his stock value. The messaging gets an F

0 · Reply

ZacksResearch Mar. 4 at 2:21 PM

$RVTY holding steady — but not without crosscurrents ⚖️ Strong diagnostics demand and fast-growing Signals software are driving momentum. At the same time, China policy pressure and weak research spending are tempering near-term growth. Is this a smart hold right now? Get the full risk/reward view here 👉 https://www.zacks.com/stock/news/2878573/heres-why-you-should-retain-revvity-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2878573-teaser-35874&ADID=SYND_STOCKTWITS_TWEET_2_2878573_TEASER_35874

0 · Reply

ZacksResearch Mar. 4 at 1:21 PM

$RVTY riding high with a 12% gain in 6 months, but is it sustainable? 📈 Revvity's Diagnostics and AI-driven software segments show strong momentum, with a 7% organic growth in diagnostics in Q4 2025 and high-teens growth in software in 2025. However, caution looms with muted 2026 growth outlook and China’s policy woes. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2878573/heres-why-you-should-retain-revvity-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2878573-body-35872&ADID=SYND_STOCKTWITS_TWEET_2_2878573_BODY_35872

0 · Reply

YouOnlyLiveTwice Mar. 3 at 6:25 PM

$RVTY When this pattern forms the stock usually rallies …last time 15 points

0 · Reply

YouOnlyLiveTwice Mar. 3 at 3:06 PM

$RVTY Down 27 points once their last WR weeks ago …. They have a conference today so the CEO will be speaking g expect more damage …amazing how blind the BOD is very sad for employees and shareholders

0 · Reply

YouOnlyLiveTwice Mar. 3 at 2:49 PM

$RVTY This is what happens when you have a horrible CFO and CEO Everytime they open their mouth the stock crashes Time to unload this garbage

0 · Reply

Streetdilly1 Mar. 3 at 12:59 AM

$FLGT why wouldnt illumina $ILMN or revity $RVTY bid $20 and take the other $6 a share in cash for free +get revenues, platform etc for free.

3 · Reply

Market Cap	9.52B
Revenue (ttm)	2.86B
Net Income (ttm)	241.20M
EPS (ttm)	N/A
PE Ratio	17.12
Forward PE	16.09
Profit Margin	8.45%
Debt to Equity Ratio	0.44

Volume	1,205,600
Avg Vol	1,066,942
Day's Range	N/A - N/A
Shares Out	111.80M
Stochastic %K	7%
Beta	1.13
Analysts	Sell
Price Target	$113.31